Overview
About AMR Accelerator
In 2019, the Innovative Medicines Initiative (IMI) launched the AMR Accelerator programme. The goal of the AMR Accelerator is to progress the development of new medicines to treat or even prevent resistant bacterial infections in Europe and worldwide.
The AMR Accelerator comprises three pillars: A Capability Building Network (the COMBINE project) will coordinate the programme and carry out research to strengthen the scientific basis in the AMR field, while the Tuberculosis Drug Development Network (the ERA4TB project) will work to accelerate the discovery of new combinations of drugs to treat TB. Finally, Portfolio Building Networks (the RespiriTB, RespiriNTM, TRIC-TB, GNA NOW and AB-Direct projects) will support collaborative efforts to discover, develop and advance new and innovative agents to prevent or treat AMR.
AMR Accelerator projects have received funding from the IMI 2 Joint Undertaking. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies’ in kind contribution.
This LinkedIn profile reflects the authors’ views and neither IMI nor the European Union, EFPIA or any Associated Partners are responsible for any use that may be made of the information contained herein.
https://www.imi.europa.eu/
The AMR Accelerator comprises three pillars: A Capability Building Network (the COMBINE project) will coordinate the programme and carry out research to strengthen the scientific basis in the AMR field, while the Tuberculosis Drug Development Network (the ERA4TB project) will work to accelerate the discovery of new combinations of drugs to treat TB. Finally, Portfolio Building Networks (the RespiriTB, RespiriNTM, TRIC-TB, GNA NOW and AB-Direct projects) will support collaborative efforts to discover, develop and advance new and innovative agents to prevent or treat AMR.
AMR Accelerator projects have received funding from the IMI 2 Joint Undertaking. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies’ in kind contribution.
This LinkedIn profile reflects the authors’ views and neither IMI nor the European Union, EFPIA or any Associated Partners are responsible for any use that may be made of the information contained herein.
https://www.imi.europa.eu/